Predicting respiratory failure for COVID-19 patients in Japan: a simple clinical score for evaluating the need for hospitalisation

Abstract

Predicting the need for hospitalisation of patients with coronavirus disease 2019 (COVID-19) is important for preventing healthcare disruptions. This observational study aimed to use the COVID-19 Registry Japan (COVIREGI-JP) to develop a simple scoring system to predict respiratory failure due to COVID-19 using only underlying diseases and symptoms. A total of 6873 patients with COVID-19 admitted to Japanese medical institutions between 1 June 2020 and 2 December 2020 were included and divided into derivation and validation cohorts according to the date of admission. We used multivariable logistic regression analysis to create a simple risk score model, with respiratory failure as the outcome for young (18–39 years), middle-aged (40–64 years) and older (≥65 years) groups, using sex, age, body mass index, medical history and symptoms. The models selected for each age group were quite different. Areas under the receiver operating characteristic curves for the simple risk score model were 0.87, 0.79 and 0.80 for young, middle-aged and elderly derivation cohorts, and 0.81, 0.80 and 0.67 in the validation cohorts. Calibration of the model was good. The simple scoring system may be useful in the appropriate allocation of medical resources during the COVID-19 pandemic.

Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study

“…In the beginning of the pandemic, almost all patients with COVID-19 were hospitalised; however, as the spread of the infection progressed, the target population for hospitalisation was changed to patients with or at risk of severe disease. 4 …”

Predictive Model of Risk Factors of High Flow Nasal Cannula Using Machine Learning in COVID-19

“…In Japan, where at-home oxygen facilities and oxygen stations have been established, the efficiency of health resource distribution needs to be improved; therefore, this study targeted patients who ultimately required nasal high flow or higher, which require inpatient management. The AUC, AUCPR, sensitivity and specificity had higher accuracy than the model used for assessing risk scores in the Japanese treatment guideline and were therefore considered to be quite satisfactory results [5,17]. The use of machine learning meant that features could be used in the statistical model without limiting their number, which helped to improve the accuracy [18].…”

Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan

“…For instance, Japanese indications for hospitalisation are quite different from those of other countries [8,25,26]; therefore, it is difficult to apply our results directly to different settings. In addition, the hospitalisation criteria in Japan have been changing over the COVID-19 pandemic time [27]. Initially, the indication of remdesivir in Japan was limited to severe COVID-19 cases [28].…”